Dynamic mRNA expression of donor‐derived activating KIR genes and their significant effects on clinical outcome after haematopoietic stem cell transplantation

2021 ◽  
Author(s):  
Ying Li ◽  
Tian Wang ◽  
Hu Xing ◽  
Huanhuan Zhang ◽  
Xiaojing Bao ◽  
...  
Keyword(s):  
Stem Cell ◽  
Clinical Outcome ◽  
Stem Cell Transplantation ◽  
Mrna Expression ◽  
Cell Transplantation ◽  
Haematopoietic Stem Cell Transplantation ◽  
Haematopoietic Stem Cell ◽  
Kir Genes

scholarly journals Activating killer-cell immunoglobulin-like receptor haplotype influences clinical outcome following HLA-matched sibling haematopoietic stem cell transplantation

HLA ◽  
2018 ◽  
Vol 92 (2) ◽  
pp. 74-82 ◽  
Author(s):  
Susan L. Heatley ◽  
Charles G. Mullighan ◽  
Kathleen Doherty ◽  
Silke Danner ◽  
Geraldine M. O'Connor ◽  
...  
Keyword(s):  
Stem Cell ◽  
Clinical Outcome ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Haematopoietic Stem Cell Transplantation ◽  
Killer Cell ◽  
Haematopoietic Stem Cell ◽  
Matched Sibling

scholarly journals Extracoporeal photopheresis treatment of acute graft-versus-host disease following allogeneic haematopoietic stem cell transplantation

F1000Research ◽  
2016 ◽  
Vol 5 ◽  
pp. 1510 ◽  
Author(s):  
Aisling M. Flinn ◽  
Andrew R. Gennery
Keyword(s):  
Stem Cell ◽  
Clinical Outcome ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Graft Versus Host Disease ◽  
Haematopoietic Stem Cell Transplantation ◽  
Haematopoietic Stem Cell ◽  
Host Disease ◽  
Graft Versus Host ◽  
Acute Graft

Acute graft-versus-host disease (aGvHD) continues to be a major obstacle to allogeneic haematopoietic stem cell transplantation. Thymic damage secondary to aGvHD along with corticosteroids and other non-selective T lymphocyte-suppressive agents used in the treatment of aGvHD concurrently impair thymopoiesis and negatively impact on immunoreconstitution of the adaptive immune compartment and ultimately adversely affect clinical outcome. Extracorporeal photopheresis (ECP) is an alternative therapeutic strategy that appears to act in an immunomodulatory fashion, potentially involving regulatory T lymphocytes and dendritic cells. By promoting immune tolerance and simultaneously avoiding systemic immunosuppression, ECP could reduce aGvHD and enable a reduction in other immunosuppression, allowing thymic recovery, restoration of normal T lymphopoiesis, and complete immunoreconstitution with improved clinical outcome. Although the safety and efficacy of ECP has been demonstrated, further randomised controlled studies are needed as well as elucidation of the underlying mechanisms responsible and the effect of ECP on thymic recovery.

scholarly journals Impact of Early Chimerism Status on Clinical Outcome in Children with Acute Lymphoblastic Leukaemia after Haematopoietic Stem Cell Transplantation

2019 ◽  
Author(s):  
Monika Lejman ◽  
Agnieszka Zaucha-Prażmo ◽  
Joanna Zawitkowska ◽  
Aleksandra Mroczkowska ◽  
Dominik Grabowski ◽  
...  
Keyword(s):  
Stem Cell ◽  
Clinical Outcome ◽  
Stem Cell Transplantation ◽  
Acute Lymphoblastic Leukaemia ◽  
Cell Transplantation ◽  
Lymphoblastic Leukaemia ◽  
Haematopoietic Stem Cell Transplantation ◽  
Haematopoietic Stem Cell ◽  
Mixed Chimerism ◽  
Donor Chimerism

Abstract Background: The significance of very early chimerism assessment before day +28, which is considered the moment of engraftment, is still unclear. In this retrospective study, we evaluated the clinical impact of very early chimerism on the clinical outcome after allogeneic haematopoietic stem cell transplantation (allo-HSCT) in children with acute lymphoblastic leukaemia (ALL). Methods: The study group included 38 boys and 18 girls. Very early chimerism was evaluated on days +7, +14, +21 and +28 after the transplant. Short tandem repeat polymerase chain reaction (STR PCR) was used to analyse chimerism. Results: Overall survival (OS) and event-free survival (EFS) were 84% and 80%, respectively. OS in the group of 24 patients with complete donor chimerism on day +14 was 83%, and it did not differ statistically compared to the 32 patients with mixed chimerism on day +14 (OS was 84%). The donor type (matched unrelated) and sex (male), number of transplanted cells (above 4.47 x 10 6 kg; on day +14) and serotherapy (without anti-thymocyte globulin)ATG were statistically related to a higher level of donor chimerism. Acute graft versus host disease grades II-IV was diagnosed in 23 patients who presented with donor chimerism levels above 60% on day 7. Conclusion: The data presented in this study provide valuable insight into the analysis of very early chimerism in children with ALL treated with HSCT.

scholarly journals Impact of Early Chimerism Status on Clinical Outcome in Children with Acute Lymphoblastic Leukaemia after Haematopoietic Stem Cell Transplantation

2019 ◽  
Author(s):  
Monika Lejman ◽  
Agnieszka Zaucha-Prażmo ◽  
Joanna Zawitkowska ◽  
Aleksandra Mroczkowska ◽  
Dominik Grabowski ◽  
...  
Keyword(s):  
Stem Cell ◽  
Clinical Outcome ◽  
Stem Cell Transplantation ◽  
Acute Lymphoblastic Leukaemia ◽  
Cell Transplantation ◽  
Lymphoblastic Leukaemia ◽  
Haematopoietic Stem Cell Transplantation ◽  
Haematopoietic Stem Cell ◽  
Donor Number ◽  
Donor Chimerism

Abstract Background: The significance of very early chimerism assessment before day +28, which is considered the moment of engraftment, is still unclear. In this retrospective study, we evaluated the clinical impact of very early chimerism on the clinical outcome after allogeneic haematopoietic stem cell transplantation (allo-HSCT) in children with acute lymphoblastic leukaemia (ALL). Methods: The study group included 38 boys and 18 girls. Very early chimerism was evaluated on days +7, +14, +21 and +28 after the transplant. Short tandem repeat polymerase chain reaction (STR PCR) was used to analyse chimerism. Results: Overall survival (OS) and event-free survival (EFS) were 84% and 80%, respectively. The OS in the group of 24 patients with complete donor chimerism on day +14 was 83%, and it did not differ statistically compared to the 32 patients with mixed chimerism on day +14 (OS was 84%). In our cohort of patients, the matched unrelated donor, male of donor, number of transplanted cells above 4.47 x 106 kg and no serotherapy with ATG were statistically related to a higher level of donor chimerism. The immunophenotypes of disease, age of patient at time HSCT, recipient sex, stem cell source (peripheral blood/bone marrow) and conditioning regimen had no impact on early chimerism. Acute graft versus host disease grades II-IV was diagnosed in 23 patients who presented with donor chimerism levels above 60% on day 7. Conclusion: The data presented in this study provide valuable insight into the analysis of very early chimerism in children with ALL treated with HSCT.

scholarly journals Impact of early chimerism status on clinical outcome in children with acute lymphoblastic leukaemia after haematopoietic stem cell transplantation

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Monika Lejman ◽  
Agnieszka Zaucha-Prażmo ◽  
Joanna Zawitkowska ◽  
Aleksandra Mroczkowska ◽  
Dominik Grabowski ◽  
...  
Keyword(s):  
Stem Cell ◽  
Clinical Outcome ◽  
Stem Cell Transplantation ◽  
Acute Lymphoblastic Leukaemia ◽  
Cell Transplantation ◽  
Lymphoblastic Leukaemia ◽  
Haematopoietic Stem Cell Transplantation ◽  
Haematopoietic Stem Cell ◽  
Donor Number ◽  
Donor Chimerism

Abstract Background The significance of very early chimerism assessment before day + 28, which is considered the moment of engraftment, is still unclear. In this retrospective study, we evaluated the clinical impact of very early chimerism on the clinical outcome after allogeneic haematopoietic stem cell transplantation (allo-HSCT) in children with acute lymphoblastic leukaemia (ALL). Methods The study group included 38 boys and 18 girls. Very early chimerism was evaluated on days + 7, + 14, + 21 and + 28 after the transplant. Short tandem repeat polymerase chain reaction (STR PCR) was used to analyse chimerism. Results Overall survival (OS) and event-free survival (EFS) were 84 and 80%, respectively. The OS in the group of 24 patients with complete donor chimerism on day + 14 was 83%, and it did not differ statistically compared to the 32 patients with mixed chimerism on day + 14 (OS was 84%). In our cohort of patients, the matched unrelated donor, male gender of donor, number of transplanted cells above 4.47 × 106 kg and no serotherapy with anti-thymocyte globulin (ATG) were statistically related to a higher level of donor chimerism. The immunophenotypes of disease, age of patient at time HSCT, recipient sex, stem cell source (peripheral blood/bone marrow) and conditioning regimen had no impact on early chimerism. Acute graft versus host disease grades II-IV was diagnosed in 23 patients who presented with donor chimerism levels above 60% on day 7. Conclusions The data presented in this study provide valuable insight into the analysis of very early chimerism in children with ALL treated with HSCT.

Sign in / Sign up

Export Citation Format

Share Document